Phase 3 Lymphoma Trial, Recruiting NCT06607419 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT06607419
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children older than 1 month and younger than 18 years old
  • People who have been diagnosed with acute lymphoblastic leukemia (a type of blood cancer), confirmed by a bone marrow test
  • People whose leukemia has been identified as a specific type called "B-cell" acute lymphoblastic leukemia
  • People whose leukemia falls into one of two risk categories based on a specific lab measurement taken on day 19 of treatment — either "provisional low-risk" with a result of 0.1% or higher, or "provisional intermediate-risk" with a result of 0.01% or higher (confirm with trial site)
  • The child or their parent/guardian must be willing and able to understand and sign the consent forms approved by the Ethics Committee

Who may not be able to join:

  • People whose leukemia cells have a specific marker called "sIgM+" (confirm with trial site)
  • People whose leukemia developed from a different blood condition called chronic myeloid leukemia
  • People with Down syndrome, or a major in-born or inherited condition that affects how their organs work
  • People with a secondary leukemia (a leukemia that developed as a result of another condition or prior treatment)
  • People whose leukemia has spread to the central nervous system (brain and spinal cord)
  • People with a history of epilepsy, or who have had a seizure in the past month
  • People with a known in-born immune system deficiency or metabolic disease
  • People with a congenital heart condition that affects how well their heart pumps
  • People who have taken steroid medicines (glucocorticoids) for 14 days or more, or certain targeted medicines (ABL kinase inhibitors) for more than 7 days, within the month before joining — or who have had any chemotherapy or radiation therapy within the 3 months before joining (emergency radiation to help with breathing difficulties may be an exception)
  • People whose leukemia was classified as high risk from the very beginning of diagnosis
  • People whose lab measurement taken on day 46 of treatment shows a result of 1% or higher (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-18930830638

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
21 May 2024
Est. completion
31 May 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The flow cytometric MRD; The NGS- MRD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov